Todd Siegel
About Todd Siegel
Todd Siegel (age 66) has served on Superior Group of Companies’ Board since February 7, 2014. He is CEO of Centered Solutions, LLC (pharmacy workflow software and packaging automation) and operates Centered Solutions, Inc. (consulting/investing), bringing prior public company leadership as President/CEO/Chairman of MTS Medication Technologies (1986–2012). His background spans healthcare supply chain, software, and manufacturing, with earlier roles in diagnostic imaging and pharmaceutical sales leadership.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| MTS Medication Technologies, Inc. | President & CEO; Chairman; Director | President/CEO ~1992–2012; Chairman ~1992–2009; Director ~1986–2012 | Led public company; packaging automation and consumables; capital allocation and operational leadership |
| AMI Diagnostic Service | Account Executive | Prior to MTS | Diagnostics sales experience |
| Chamberlin Corporation | Sales and National Sales Management | Prior to MTS | Pharma sales leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Centered Solutions, LLC | Chief Executive Officer | Current | Pharmacy workflow software, supply chain integration, packaging automation |
| Centered Solutions, Inc. | Operator | Current | Consulting, investments, PE deal sourcing |
No current public company directorships disclosed for Siegel outside SGC.
Board Governance
- Independence: Board determined Siegel is independent under SEC and NASDAQ rules; all members of Compensation and Corporate Governance committees are independent.
- Committee assignments: Chair, Corporate Governance, Nominating & Ethics; Member, Compensation; Member, Capital.
- Board and committee activity: Board met 4 times in 2024; Audit (6), Corporate Governance (5), Capital (5), Compensation (2). Each director attended at least 75% of Board and applicable committee meetings; all directors attended the 2024 annual meeting.
- Lead Independent Director: Paul Mellini; chartered responsibilities include presiding over executive sessions of independent directors, agenda review, leading annual Board/committee evaluations, and investor liaison.
- Stock ownership guidelines: Independent directors must own at least $200,000 of SGC stock within five years of appointment; enforcement is at committee discretion. Compliance status by director is not disclosed.
Fixed Compensation
| Year | Cash Fees ($) | Stock Awards ($) | Option Awards ($) | All Other ($) | Total ($) |
|---|---|---|---|---|---|
| 2024 | 58,750 | 74,981 | 24,833 | — | 158,564 |
- Director pay structure (effective May 9, 2024): Board retainer $45,000; committee retainers (Audit $6,000; Corporate Governance $3,000; Compensation $3,000; Capital $2,000); chair premiums (Audit $14,000; Corporate Governance $10,000; Compensation $10,000; Capital $8,000); Lead Director $17,500; annual option grant 2,750; restricted stock: Lead Director $80,000; other non-employee directors $75,000. Per-meeting fees eliminated May 12, 2023.
Performance Compensation
| Award Type | Grant Date | Amount | Vesting | Fair Value/Terms |
|---|---|---|---|---|
| Restricted Stock (Director grant) | 2024-05-09 | 3,766 sh | Vests 2026-05-08 (service condition) | $74,981 grant-date fair value; dividends payable on unvested shares per plan |
| Stock Options (Director grant) | 2024-05-09 | 2,750 opt | Vest 2 years from grant; 10-year expiry | $24,833 grant-date fair value; strike $19.91 |
No performance metrics tied to director compensation are disclosed; director equity grants are time-based.
Other Directorships & Interlocks
| Company | Role | Committee Roles | Interlock/Conflict Notes |
|---|---|---|---|
| None disclosed | — | — | No external public boards disclosed for Siegel; no related-party transactions requiring disclosure. |
Expertise & Qualifications
- Public company leadership and capital allocation (former public CEO/Chair at MTS).
- Healthcare supply chain, packaging automation, and workflow software domain expertise (Centered Solutions).
- Governance focus and committee leadership (Chair, Corporate Governance, Nominating & Ethics).
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership | 81,854 shares; <1% of outstanding |
| Options/SARs exercisable (or within 60 days) | 24,675 shares |
| Unvested director restricted stock | 6,909 sh (granted 2022-11-04; vest 2025-11-04) ; 7,537 sh (granted 2023-11-08; vest 2026-11-08) ; 3,766 sh (granted 2024-05-09; vest 2027-05-09) |
| Ownership guidelines | Independent directors required to hold $200,000 of SGC stock within five years; compliance not disclosed |
| Pledging/hedging | Hedging/monetization transactions prohibited by insider trading policy; pledging not disclosed |
Governance Assessment
- Strengths: Independent director; chairs Corporate Governance committee; multi-committee service; attendance ≥75% with full annual meeting participation; time-based director equity enhances alignment; clear ownership guidelines; robust related-party policy with no reportable related-party transactions since 2022.
- Watch items: Concentration of governance influence via committee chair role warrants monitoring of balance among independent directors; compliance status with $200,000 director ownership guideline not disclosed; pledging policy not explicitly stated (hedging prohibited).
- Board signals: Lead Independent Director charter provides strong independent oversight mechanisms (executive sessions, evaluations, agenda review), supportive for board effectiveness.
- Say-on-pay context: Prior shareholder support for executive pay at ~89.64% (2022) indicates general investor acceptance of compensation framework; as a governance chair, Siegel’s oversight intersects compensation philosophy and shareholder alignment.
RED FLAGS: None identified specific to Siegel—no related-party transactions, no attendance shortfalls disclosed, no hedging permitted; pledging not addressed explicitly. Continue monitoring for any external business dealings involving Centered Solutions and SGC.